Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustainable return to work among breast cancer survivors.
Ruiz de Azua G, Kousignian I, Vaz-Luis I, Di Meglio A, Caumette E, Havas J, Martin E, Martin AL, Querel O, Vanlemmens L, Pistilli B, Coutant C, Cottu PH, Merimeche AD, Lerebours F, Tredan O, Jouannaud C, Levy C, Dumas A, Menvielle G. Ruiz de Azua G, et al. Among authors: cottu ph. Cancer Med. 2023 Sep;12(18):19091-19101. doi: 10.1002/cam4.6467. Epub 2023 Aug 21. Cancer Med. 2023. PMID: 37602836 Free PMC article.
[Clinical activity spectrum of irinotecan].
Cottu PH, Extra JM, Lerebours F, Espie M, Marty M. Cottu PH, et al. Bull Cancer. 1998 Dec;Spec No:21-5. Bull Cancer. 1998. PMID: 9932080 Free article. Review. French.
Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification.
Reyal F, Belichard C, Rouzier R, de Gournay E, Senechal C, Bidard FC, Pierga JY, Cottu P, Lerebours F, Kirova Y, Feron JG, Fourchotte V, Vincent-Salomon A, Guinebretiere JM, Sigal-Zafrani B, Sastre-Garau X, De Rycke Y, Coutant C. Reyal F, et al. PLoS One. 2012;7(10):e47390. doi: 10.1371/journal.pone.0047390. Epub 2012 Oct 9. PLoS One. 2012. PMID: 23056641 Free PMC article.
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.
Pivot X, Spano JP, Espie M, Cottu P, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Attar-Rabia H, Benkanoun C, Dima-Martinez L, Esposito N, Gligorov J. Pivot X, et al. Eur J Cancer. 2017 Sep;82:230-236. doi: 10.1016/j.ejca.2017.05.009. Epub 2017 Jun 23. Eur J Cancer. 2017. PMID: 28648618 Clinical Trial.
215 results